{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T20:25:50Z","timestamp":1778185550624,"version":"3.51.4"},"reference-count":14,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>This review investigates that, in 2023, fatty liver disease underwent a name change to \u201csteatotic liver disease\u201d (SLD). SLD now includes metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD), and metabolic and alcohol-related liver disease (MetALD). The renaming aims to better incorporate alcohol intake and metabolic risk factors into disease classification and to diminish the stigma associated with the previous nomenclature. Early identification of the patient\u2019s aetiology is important for the prognosis which can be improved by interventions against the causative risk factors.<\/jats:p>","DOI":"10.61409\/v12230778","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T06:31:01Z","timestamp":1715668261000},"page":"1-7","source":"Crossref","is-referenced-by-count":1,"title":["New nomenclature for fatty liver disease"],"prefix":"10.61409","author":[{"given":"Camilla Dalby","family":"Hansen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrine Prier","family":"Lindvig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henning","family":"Gr\u00f8nb\u00e6k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise Lotte","family":"Gluud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksander","family":"Krag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Rinella ME, Lazarus JV, Ratziu V et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. https:\/\/doi.org\/10.1097\/HEP.0000000000000520","DOI":"10.1097\/HEP.0000000000000520"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. https:\/\/doi.org\/10.1097\/HEP.0000000000000323","DOI":"10.1097\/HEP.0000000000000323"},{"key":"ref2","unstructured":"Hansen CD, Lindvig KP, Gr\u00f8nb\u00e6k H et al. Nonalkoholisk fedtlever-sygdom ved overv\u00e6gt og metabolisk syndrom. Ugeskr L\u00e6ger 2022;184:V04220239."},{"key":"ref3","unstructured":"Jensen HAR, Davidsen M, M\u00f8ller SR et al. Danskernes sundhed - Den Nationale Sundhedsprofil 2021, 2022. https:\/\/www.sst.dk\/-\/media\/Udgivelser\/2022\/Sundhedsprofil\/Sundhedsprofilen.ashx?sc_lang=da&hash=5C9A9A81483F6C987D5651976B72ECB2 (12. nov. 2023)."},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Eslam M, Newsome PN, Sarin SK et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202-209. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039","DOI":"10.1016\/j.jhep.2020.03.039"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Allen AM, Therneau TM, Ahmed OT et al. Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design. J Hepatol. 2022;77(5):1237-1245. https:\/\/doi.org\/10.1016\/j.jhep.2022.07.004","DOI":"10.1016\/j.jhep.2022.07.004"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Rasmussen DN, Thiele M, Johansen S et al. Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease. J Hepatol. 2021;75(5):1017-1025. https:\/\/doi.org\/10.1016\/j.jhep.2021.05.037","DOI":"10.1016\/j.jhep.2021.05.037"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Israelsen M, Juel HB, Detlefsen S et al. Metabolic and genetic risk factors are the strongest predictors of severity of alcohol-related liver fibrosis. Clin Gastroenterol Hepatol. 2020;20(8):1784-1794.e9. https:\/\/doi.org\/10.1016\/j.cgh.2020.11.038","DOI":"10.1016\/j.cgh.2020.11.038"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Israelsen M, Torp N, Johansen S et al. MetALD: new opportunities to understand the role of alcohol in steatotic liver disease. Lancet Gastroenterol Hepatol. 2023;8(10):866-868. https:\/\/doi.org\/10.1016\/S2468-1253(23)00206-6","DOI":"10.1016\/S2468-1253(23)00206-6"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver; American Association for the Study of Liver Diseases; Latin American Association for the Study of the Liver; Asian Pacific Association for the Study of the Liver. Ending stigmatizing language in alcohol and liver disease: a liver societies' statement. J Hepatol. 2023;79(6):1347-1348. https:\/\/doi.org\/10.1016\/j.jhep.2023.07.016","DOI":"10.1016\/j.jhep.2023.07.016"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Ekstedt M, Hagstr\u00f6m H, Nasr P et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547-1554. https:\/\/doi.org\/10.1002\/hep.27368","DOI":"10.1002\/hep.27368"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver; Clinical Practice Guideline Panel; Chair; EASL Governing Board representative. EASL Clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021;75(3):659-689. https:\/\/doi.org\/10.1016\/j.jhep.2021.05.025","DOI":"10.1016\/j.jhep.2021.05.025"},{"key":"ref12","unstructured":"Lindvig K, Krag A, Thiele M. Tidlig opsporing af alkoholrelateret leversygdom. Ugeskr L\u00e6ger. 2021;183:V12200947."},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. https:\/\/doi.org\/10.1097\/HEP.0000000000000323","DOI":"10.1097\/HEP.0000000000000323"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T10:41:43Z","timestamp":1715769703000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V12230778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":14,"URL":"https:\/\/doi.org\/10.61409\/v12230778","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"value":"0041-5782","type":"print"},{"value":"1603-6824","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]}}}